Application of composition in diagnosis of triple negative breast cancer

A composition and technology of breast cancer, applied in the direction of microbial measurement/testing, biochemical equipment and methods, etc., can solve the problems of tracking, not being able to be used as the prognostic effect of breast cancer, and limited diagnostic value of breast cancer, so as to increase the sensitivity of chemotherapy Effect

Inactive Publication Date: 2016-12-07
CANCER CENT OF GUANGZHOU MEDICAL UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although breast cancer has a relatively good molecular classification, this molecular classification is based on breast cancer tissue detection and cannot be used as a follow-up for breast cancer prognosis
[0005] Moreover, due to the diversity of breast cancer histopathology, the heterogeneity of tumor cells with the same pathology, and the complexity and polymorphism of tumor biological behavior, the diagnostic value of single marker detection for breast cancer is limited, and it c

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition in diagnosis of triple negative breast cancer
  • Application of composition in diagnosis of triple negative breast cancer
  • Application of composition in diagnosis of triple negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0027] Example 1

[0028] Use miRNA-specific PCR detection, that is, extract cell miRNAs and reverse transcription, then use real-time quantitative PCR to detect, see the results Figure 1-Figure 3 As shown, the results found that the expression levels of miR-141, miR-200a and miR-145 in the triple negative breast cancer cell lines MDA-MB-231, BT-549, SUM1315 and Hs578T were significantly lower than those of Luminal MCF7, T47D and BT474 Cell lines, as well as HER2 overexpression SKBR3 cell lines, and lower than normal breast epithelial cells HMLE.

Example Embodiment

[0029] Example 2

[0030] After removing the relevant tissues from liquid nitrogen and making a tissue homogenate, the tissue miRNAs are extracted and reverse transcribed, and then detected by real-time quantitative PCR, and 72 pairs of cancer and adjacent normal breast cancer tissues are detected by miRNA-specific qRT-PCR (43 cases of Luminal type, 29 cases of triple-negative type) expression of miR-141, miR-200a and miR-145, please refer to the test results Figure 4 As shown, the results showed that compared with paired normal tissues adjacent to cancer, the expression of miR-141, miR-200a and miR-145 in triple negative breast cancer (TNBC) tissues was significantly lower than that in Luminal breast cancer tissues.

Example Embodiment

[0031] Example 3

[0032] The expression of miR-141, miR-200a and miR-145 in breast cancer tissues was detected by miRNA-specific in situ hybridization (ISH, insituhybridizations, target miRNAs stained blue, and nuclei stained red). See the results Figure 5 As shown, the results found that compared with normal breast tissue, Luminal A breast cancer tissue, Luminal B breast cancer tissue and HER2-positive breast cancer tissue, miR-141, miR-200a and miR-145 are in triple-negative breast tissue The expression in cancer tissues was significantly down-regulated.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a composition in diagnosis of triple negative breast cancer. The composition comprises miR-141, miR-200a and miR-145. It is proved for the first time that expression of the combination of miR-141, miR-200a and miR-145 is regulated down mainly in triple negative breast cancer. Meanwhile, the content of the combination of miR-141, miR-200a and miR-145 in serum of a patient with triple negative breast cancer is obviously reduced compared with that in serum of breast cancer patients of other molecular subtyping. New data are provided for breast cancer molecular subtyping, a new target point and a serum fast detection method are provided for detection of triple negative breast cancer molecular subtyping.

Description

technical field [0001] The invention relates to a biomarker of breast cancer, in particular to the application of a composition in the diagnosis of triple negative breast cancer. Background technique [0002] Breast cancer is currently one of the most common and deadly malignant tumors in the world, and its morbidity and mortality are increasing rapidly. In order to reduce the mortality rate of breast cancer patients, in addition to reducing the incidence rate in terms of etiological prevention, improving the level of early diagnosis and the efficacy of drug treatment are two important aspects. However, the early diagnosis of lung cancer has always been a worldwide problem. At present, imaging diagnosis (B-ultrasound, mammography), chemical diagnosis (cancer response, serological and immunological indicators) and histocytological diagnosis are the three pillars of tumor diagnosis. The former has great limitations in subclinical diagnosis, while the latter two use tumor mark...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/158C12Q2600/178
Inventor 郑国沛贺智敏张志杰李洪胜邱霓
Owner CANCER CENT OF GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap